Abbreviated Name

PASS Ref Set App: Caveolin-1

Lead Investigator

Lin UW, Daniel W. — University of Washington

Coordinating Investigator

Lin UW, Daniel W. — University of Washington

Involved Investigators

• Lin UW, Daniel W. — University of Washington

Abstact

Prostate cancer is the most frequently diagnosed solid tumor in men, and over 75% of men have localized disease at diagnosis. The majority of these (>50%) have tumors amenable to active surveillance, a management strategy that limits morbidity associated with local treatment while safely monitoring men with aggressive disease who are at risk of progression. Active surveillance is not without costs, however, as up to 40% of men ultimately undergo invasive treatment that can affect quality of life. The most frequent reason men on active surveillance elect delayed treatment is pathologic disease progression. Therefore, the development of non-invasive markers of disease progression are of paramount importance in the management of men on active surveillance. Furthermore, discovery of markers that are: 1) linked directly to tumor biology, and 2) are responsive to non-invasive interventions such as dietary change would have tremendous implications for men managed on active surveillance. Our group developed a biomarker signature associated with progression on active surveillance that is based on caveolin-1 (Cav-1), a cell membrane structural component associated with prostate cancer aggressiveness, coupled with a validated lipidomics profile (“Cav-1-lipid signature”). Mechanistically, the Cav-1-lipid signature is excreted by prostate tumor cell lines following lipid metabolism, and signature components are increased in animal models that consume a high-fat diet. A parallel investigation within our clinical cohort of men on active surveillance showed that diet may modulate risk of progression in men with a high-risk Cav-1-lipid signature. We therefore hypothesize that external validation using the information from the CANARY prostate cancer cohort will confirm that the Cav-1-lipid signature is associated with progression in men on active surveillance.

Aims

Validate the association between Cav-1-sphingolipid signature level and progression on active surveillance using a cohort of men enrolled on a prospective active surveillance trial.

Analytic Method

No analytic method available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

Start Date

Dec 1 2021

Estimated Finish Date

Dec 1 2022

Finish Date

Dec 31 2020

Protocol ID

501

Protocol Type

Validation

Field of Research

Proteomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate